Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.130 +0.050 (+2.40%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,434,864
Open 2.110
Bid (Size) 2.120 (100)
Ask (Size) 2.130 (3,500)
Prev. Close 2.080
Today's Range 2.070 - 2.160
52wk Range 1.830 - 5.430
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know ↗
A major fund just opened a multimillion-dollar position in ImmunityBio—and the move could hint at rising confidence in this clinical-stage immunotherapy pipeline. 
Via The Motley Fool
News headline image
Heights Capital Walks From Archer Aviation: What It Means for Investors ↗
One major investor just walked away from Archer Aviation. Here’s what that move does—and doesn’t—signal for the future of urban air mobility. 
Via The Motley Fool

Performance

YTD
-17.1%
-17.1%
1 Month
-19.9%
-19.9%
3 Month
-10.5%
-10.5%
6 Month
-15.8%
-15.8%
1 Year
-57.7%
-57.7%

More News

Read More
News headline image
Heights Capital Just Ditched Its $12.5 Million AMSC Stake. Here’s What That Might Mean. ↗
Via The Motley Fool
ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals ↗
Via Stocktwits
News headline image
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
From ImmunityBio, Inc.
Via Business Wire
News headline image
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
From ImmunityBio, Inc.
Via Business Wire
News headline image
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks ↗
Via Benzinga
News headline image
Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗
Via MarketBeat
Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts ↗
Via Stocktwits
News headline image
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
From ImmunityBio, Inc.
Via Business Wire
News headline image
What's Going On With ImmunityBio Shares Tuesday? ↗
Via Benzinga
News headline image
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients
From ImmunityBio, Inc.
Via Business Wire
News headline image
IBRX Sales Soar 2,540% ↗
Via The Motley Fool
News headline image
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
From ImmunityBio, Inc.
Via Business Wire
News headline image
LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper ↗
Via Benzinga
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via Investor Brand Network
News headline image
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via FinancialNewsMedia
Topics Death
News headline image
UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
From ImmunityBio, Inc.
Via Business Wire
News headline image
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
From ImmunityBio, Inc.
Via Business Wire
News headline image
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?
Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
What exchange does ImmunityBio, Inc. - Common Stock trade on?
ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 2.130
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 11/26/25 04:00 PM ET
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 833.16M
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 833M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.